Exploring the 5 FDA-Approved IUDs: Types, Benefits, and Effectiveness

Copper IUDs 

Copper IUDs are hormone-free and primarily work by using the natural properties of copper to create an environment toxic to sperm. While copper IUDs provide longer-term contraception than hormonal IUDs, they have a slightly higher failure rate. 

ParaGard 

ParaGard, manufactured by Teva Women's Health Pharmaceuticals, received FDA approval in 1984 and has been accessible in the US since 1988. ParaGard is non-hormonal and contains copper, making it the oldest IUD and copper IUD approved by the FDA.

Measuring 32 mm horizontally and 36 mm vertically, with a 3 mm diameter bulb at the tip of the vertical stem, ParaGard provides long-term contraception by preventing sperm from reaching and fertilizing the egg. ParaGard is approved for a maximum of 10 years, but evidence-based use suggests it can be effective for 12–20 years. The average cost of ParaGard is around $1,071 without insurance.

For the first year, the copper IUD demonstrates effectiveness like tubal sterilization. ParaGard’s first-year failure rate ranges from 0.5% to 0.8%; at 7 years, the failure rate ranges from 1.4% to 2.2%. At 12 years, the cumulative failure rate is 2.2%.  

Hormonal IUDs  

The four FDA-approved hormonal IUDs include Mirena, Skyla, Liletta, and Kyleena, which release a progestin hormone — levonorgestrel — into the uterus. The hormone thickens the cervical mucus, which prevents sperm from reaching the egg, and also thins the uterine lining to make it less receptive to implantation. Hormonal IUDs can provide contraception for various durations, ranging between 3 and 8 years. 

Hormonal IUDs offer benefits related to reproductive health aside from contraception. They are often prescribed to individuals with endometriosis, chronic pelvic pain, and heavy periods. Many people also choose hormonal IUDs since they may lessen period pain, reduce period frequency, or eliminate menstruation. 

Research suggests that IUDs can be safely and effectively provided to individuals with a uterus who have not given birth, even though they are not officially approved for this group. 

Mirena  

Mirena, manufactured by Bayer Healthcare Pharmaceuticals, was initially approved by the FDA as a long-acting contraceptive on December 6, 2000. On October 2, 2009, it received additional approval for treating heavy menstrual bleeding among IUD users. The FDA extended its approval for pregnancy prevention up to 7 years on August 25, 2021. Then, on August 18, 2022, the FDA made Mirena the longest-lasting hormonal IUD available in the American market by extending approval for up to 8 years. 

With a failure rate of up to 1.1%, Mirena prevents pregnancy by reducing ovulation frequency, thickening cervical mucus, impeding sperm movement into the uterus, and inhibiting sperm from binding to an egg.

Mirena comprises 52 mg of levonorgestrel, initially releasing approximately 20 µg/day. This release rate gradually reduces to half its initial value over 5 years. The cost of Mirena without insurance is roughly $1272. 

Skyla  

Skyla — approved by the FDA in early 2013 — is one of the two smallest-sized hormonal intrauterine devices. Its 13.5 mg levonorgestrel release is considered a more suitable option for individuals who have never given birth. Its functioning and failure rate (up to 0.9%) resemble Mirena. Due to its slow-release mechanism, only small amounts of levonorgestrel enter the bloodstream, making it a better option for patients sensitive to hormones.  

Skyla, manufactured by Bayer, is approved for up to 3 years. The dimensions of its T-body are 28 mm × 30 mm, and the outer diameter of the placement tube is 3.8 mm. Skyla retails for $975. 

Liletta  

Liletta, approved in 2015, is another hormonal IUD that slowly releases levonorgestrel. It works similarly to Mirena and Skyla but is approved for up to 6 years of use. Liletta has a failure rate of up to 1.1% and retails for around $892.  

Developed by Actavis in collaboration with Medicines360, a non-profit women's pharmaceutical company, to provide an affordable IUD option, Liletta is made accessible to public health clinics enrolled in the national 340B Drug Pricing Program, offering significant discounts. The 340B program enables providers serving low-income populations to obtain pharmaceuticals at reduced costs.  

Kyleena  

Kyleena, the latest to gain FDA approval in September 2016, also slowly releases a low dose of levonorgestrel, providing contraception for up to 5 years. Like Mirena and Skyla, Kyleena is also manufactured by Bayer but distinguishes itself from Mirena by containing lower levels of hormones. Kyleena has a failure rate of up to 1.6% and retails for $1,321. 

Table 1. US FDA-Approved IUDs

Insertion—Removal Costs and Side Effects 

According to the Student Life University Health Service at the University of Michigan, inserting any of these devices costs $202. In contrast, removing an existing device is priced at $210. If both removal and insertion of a new device are required, the combined cost is $649. 

These prices may vary depending on the healthcare provider and insurance coverage. Verifying the current pricing with a patient’s healthcare provider or insurance company is advisable. 

For those with health insurance, the Affordable Care Act (Obamacare) ensures that hormonal and non-hormonal IUDs are available for free or at a reduced cost. The Act mandates insurance plans to cover at least one of the 18 FDA-approved birth control methods. 

Insurance plans are required to provide coverage for these services without requiring any copayment, coinsurance, or meeting the deductible as long the provider is in-network. 

“The risks/side effects of any IUD after placement include cramping, bleeding between your periods, infection in the uterus, a uterine perforation (a hole in the wall of the uterus), unintended pregnancy, and expulsion or rejection of the IUD,” explained Galey. “In addition, the side effects of the copper IUD include a slight increase in bleeding each month. Additional side effects of a progestin IUD include having no period.” 

Uterine perforation resulting from the insertion of an intrauterine device is rare, observed in approximately 1 out of every 1,000 insertions. Perforation can manifest as either complete, where the device is entirely within the abdominal cavity, or partial, with the device partially embedded to varying extents within the uterine wall. 

Conversely, some studies suggest that IUD use may decrease the risk of certain gynecological cancers, such as ovarian and endometrial. These additional benefits make IUDs a versatile option for reproductive health beyond their primary use as a contraceptive method.